Results 211 to 220 of about 59,797 (283)

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Endothelium‐ and epithelium‐derived novel endogenous catecholamines as modulators of the autonomic nervous system

British Journal of Pharmacology, EarlyView.
Abstract Catecholamines are classically viewed as neuronal transmitters and adrenal hormones; however, accumulating evidence demonstrates that sources other than nerve fibres and adrenal medulla play a fundamental role in local organ regulation. Physiological paradoxes, such as preserved organ function after denervation or transplantation, challenge a ...
Mariana G. de Oliveira, Edson Antunes, Fabiola Zakia Monica, Gilberto De Nucci   +3 more
wiley   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

ACTH suppression and adverse effects of cabergoline in horses with pituitary pars intermedia dysfunction

Equine Veterinary Education, EarlyView.
Summary Background The diagnosis and management of pituitary pars intermedia dysfunction (PPID) in horses includes evaluating abnormal plasma concentrations of adrenocorticotrophic hormone (ACTH). Treatment commonly includes the oral dopamine agonist pergolide mesylate, which suppresses the pathologic overproduction of ACTH.
A. Bracken, H. Tyra, M. Vetter, K. Kiger, S. Rao, L. Bass   +5 more
wiley   +1 more source

Iloperidone treatment mitigates the Juvenile Huntington's Disease phenotype possibly via Sigma‐1 Receptor Modulation

The FEBS Journal, EarlyView.
We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...
Ersilia Fornetti, Gaia Galluzzi, Mario Frezzini, Cécile Exertier, Vittorio Brufani, Gianni Colotti, Giancarlo Ruocco, Jessica Rosati, Angelo Luigi Vescovi, Daniele Narzi, Ilaria Genovese, Andrea Ilari   +11 more
wiley   +1 more source

Gastroenterological Society of Australia Position Statement on the Assessment and Management of Idiopathic Gastroparesis

Journal of Gastroenterology and Hepatology, EarlyView.
The first Australian guidance document on the assessment and management of idiopathic gastroparesis (IGP) reconceptualises IGP as a sensorimotor disorder. It proposes a novel multidisciplinary treatment algorithm and 20 high‐consensus recommendations, addressing common overlapping disorders, and providing clear guidance on associated disordered eating ...
Trina Kellar, Chamara Basnayake, Jessica Biesiekierski, Rebecca Burgell, Jessica Fitzpatrick, Geoffrey Hebbard, Vincent Ho, Hannah Kim, Simon R. Knowles, Christopher K. Rayner, May Wong, Nicholas J. Talley   +11 more
wiley   +1 more source

Lower density of calretinin‐immunopositive neurons in the putamen of subjects with schizophrenia

Journal of Anatomy, Volume 246, Issue 4, Page 505-516, April 2025.
Recent neuroimaging and histological studies highlight the striatum as a key area involved in SCH, but the specific impairment of neuronal subtypes in subcortical structures is not fully understood. This study is the first detailed investigation of neuroanatomical changes in the putamen in SCH, specifically examining the density of calretinin ...
Paz Kelmer, Paulina Hoppa, Erzsébet Frank, Teadora Tyler, Istvan Adorjan   +4 more
wiley   +1 more source

Harnessing the Therapeutic Potential of Cell Secretomes and Extracellular Vesicles for Craniofacial Regenerative Applications

Journal of Periodontal Research, EarlyView.
The scoping review summarizes the current preclinical and clinical evidence for the use of “cell‐free” therapies in craniofacial (periodontal, bone and soft‐tissue) regeneration. It also aims to highlight key challenges and strategies towards the clinical translation of these therapies.
Siddharth Shanbhag, Magdalena Mayol, Danijel Domic, Madhusudhan Reddy Bobbili, Johannes Grillari, Mariano Sanz, Reinhard Gruber   +6 more
wiley   +1 more source